Response letter to "Latent class analysis of 216 patients with adult-onset Still's disease" by Sugiyama et al.
Adult-onset Still’s disease
Myelodysplastic syndrome
VEXAS
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
28 12 2022
28 12 2022
Historique:
received:
03
02
2022
accepted:
10
02
2022
entrez:
28
12
2022
pubmed:
29
12
2022
medline:
31
12
2022
Statut:
epublish
Résumé
Sugiyama et al. recently described in "Latent class analysis of 216 patients with adult-onset Still's disease," baseline characteristics, laboratory tests, treatment, relapse, and death of adult-onset Still's disease (AOSD) patients from a Japanese hospital. They identified two subgroups: Class 1 (n=155) with a younger age and typical symptoms of AOSD and Class 2 (n=61) with older patients and fewer typical symptoms of AOSD. In 2022, VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, an established X-linked disease associated with a somatic mutation in UBA1, is considered as a differential diagnosis for AOSD particularly in elderly. These patients from Class 2 could benefit from more explorations for mild myelodysplasia and VEXAS.
Identifiants
pubmed: 36578047
doi: 10.1186/s13075-022-02984-7
pii: 10.1186/s13075-022-02984-7
pmc: PMC9795768
doi:
Types de publication
Letter
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
285Commentaires et corrections
Type : CommentOn
Informations de copyright
© 2022. The Author(s).
Références
Expert Rev Clin Immunol. 2018 May;14(5):351-365
pubmed: 29658384
J Allergy Clin Immunol. 2022 Jan;149(1):432-439.e4
pubmed: 34048852
J Clin Med. 2021 Nov 27;10(23):
pubmed: 34884286
Rev Med Interne. 2020 Mar;41(3):168-179
pubmed: 31924392
N Engl J Med. 2020 Dec 31;383(27):2628-2638
pubmed: 33108101
Br J Dermatol. 2022 Mar;186(3):564-574
pubmed: 34632574